As the first-ever Medicare drug-price negotiations take shape, Big Pharma-backed Democrats want to limit the number of costly medicines regulators can target.
Democratic Reps. Scott Peters (Calif.), Wiley Nickel (N.C.), Josh Gottheimer (N.J.) and Donald Davis (N.C.) are each co-sponsoring at least one of several proposed bills that would limit regulators’ ability to negotiate down prices of drugs covered by the Medicare government insurance program. The legislation would erode the drug-pricing reforms included in the Democrats’ 2022 Inflation Reduction Act — efforts that Peters, Nickel, and Gottheimer supported. (Davis had not yet been elected to Congress.)
The four, who all hail from states with a major biotech or drug-industry presence, have together raked in more than $300,000 from pharmaceutical and health-products interests during the 2023-2024 congressional session. Gottheimer is reportedly eyeing a 2025 gubernatorial run in New Jersey, home to the pharmaceutical giant Merck & Co.
Recent Posts
‘ICE Has Gone Rogue’: Khanna Demands Arrest, Prosecution of Jonathan Ross for Murder of Renee Good
Take Action Now “We need to hold ICE accountable and we need to uphold human rights in ICE facilities. This is the time for Americans to speak up.”……
Right Message, Wrong Messengers: A Brief History Of Oil And U.S. Empire In Iran
Take Action Now Since 1979, the U.S. has pursued policies aimed at ensuring the failure of the Iranian Revolution.By Eric Ross, Z Network Multiple…
Trump Intensifies Threats Against Cuba
Take Action Now The US president warned Cuban authorities that if they do not engage in dialogue, it will soon be “too late.” Cuban authorities have…
‘Uninvestable’: Oil Execs Rebuff Trump’s Demands For $100bn Investment In Venezuela
Take Action Now The US Energy Secretary denies ‘stealing’ Venezuelan oil, despite a plan to hold revenues in offshore accounts under US…